Glaxo Files Two Melanoma Drugs for U.S., Europe Approvals

GlaxoSmithKline Plc, the U.K.’s largest drugmaker, said it submitted two experimental melanoma medicines to regulators in the U.S. and Europe for approval following trials that it deemed successful two months ago.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.